Loading...
  • patients
  • ELZONRIS (tagraxofusp-erzs), a CD123-directed cytotoxin, is approved by the U.S. Food and Drug Administration ( FDA ) and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). (stemline.com)
  • ELZONRISā„¢ (tagraxofusp), a targeted therapy directed to CD123, is FDA -approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). (stemline.com)
  • ELZONRIS (tagraxofusp) is FDA -approved for the treatment of patients, adults and pediatric 2 years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN), and is commercially available in the U.S. (stemline.com)